|Cynthia L. Comella, MD, FAAN
||Dr. Comella has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz Pharmaceutical, Revance Therapeutic, Retrophin Therapeutic, Acorda Therapeutics, Allergan, Inc., Lundbeck Ltd., Medtronic, Merz Pharmaceuticals, Acadia Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences Inc. and Revance Therapeutic. Dr. Cornella has received (royalty or license fee or contractual rights) payments from Cambridge and Wolters Kluwer. Dr. Comella has received research support from Acorda, Revance, Merz and Eisai.
|Deborah Hall, MD, PhD, FAAN
||Dr. Hall has received personal compensation in an editorial capacity from the American Academy of Neurology. Dr. Hall has received research support from Neurocrine, Pfizer and Abbvie.